Literature DB >> 1732411

Macrophage priming and lipopolysaccharide-triggered release of tumor necrosis factor alpha during graft-versus-host disease.

F P Nestel1, K S Price, T A Seemayer, W S Lapp.   

Abstract

In this report we have investigated macrophage (M phi) activity and tumor necrosis factor alpha (TNF-alpha) production during graft-vs.-host disease (GVHD). TNF-alpha production by M phi requires two signals: priming of M phi by interferon followed by triggering of TNF-alpha production and release by lipopolysaccharide (LPS). The state of M phi activation was examined in nonirradiated B6AF1 recipient mice injected with either 60 x 10(6) (acute GVHD) or 30 x 10(6) (nonlethal GVHD) parental B6 lymphoid cells. During the early phase of acute GVHD, administration of normally sublethal amounts of LPS-triggered release of significant amounts of TNF-alpha into the serum resulting in death of the animals within 36 h. Normal animals treated with the same dose of LPS neither died nor produced detectable amounts of serum TNF-alpha. In vitro studies demonstrated that M phi were primed during GVHD. The level of M phi priming was greater during acute GVHD than nonlethal GVHD since 100-fold less LPS was required to trigger killing of a TNF-alpha-sensitive cell line by M phi from acute GVHD animals. The amount of TNF-alpha released into the serum after LPS injection increased during the course of the GVHD and was significantly greater in acute GVH-reactive mice. Endogenous LPS was detected in the serum of acute GVH-reactive animals coincident with the onset of mortality. The data provide evidence that during GVHD M phi are primed as a result of the allogeneic reaction and that endogenous LPS therefore triggers M phi production of TNF-alpha resulting in the symptoms characteristic of acute GVHD.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1732411      PMCID: PMC2119110          DOI: 10.1084/jem.175.2.405

Source DB:  PubMed          Journal:  J Exp Med        ISSN: 0022-1007            Impact factor:   14.307


  60 in total

1.  Serum tumor necrosis factor alpha associated with acute graft-versus-host disease in humans.

Authors:  F W Symington; M S Pepe; A B Chen; A Deliganis
Journal:  Transplantation       Date:  1990-09       Impact factor: 4.939

2.  Immunosuppression and lymphoid hypoplasia associated with chronic graft versus host disease is dependent upon IFN-gamma production.

Authors:  G R Klimpel; C R Annable; M G Cleveland; T R Jerrells; J C Patterson
Journal:  J Immunol       Date:  1990-01-01       Impact factor: 5.422

3.  Structure and function of lipopolysaccharide binding protein.

Authors:  R R Schumann; S R Leong; G W Flaggs; P W Gray; S D Wright; J C Mathison; P S Tobias; R J Ulevitch
Journal:  Science       Date:  1990-09-21       Impact factor: 47.728

4.  Increased serum levels of tumor necrosis factor alpha precede major complications of bone marrow transplantation.

Authors:  E Holler; H J Kolb; A Möller; J Kempeni; S Liesenfeld; H Pechumer; W Lehmacher; G Ruckdeschel; B Gleixner; C Riedner
Journal:  Blood       Date:  1990-02-15       Impact factor: 22.113

5.  Comparison of in vitro cell cytotoxic assays for tumor necrosis factor.

Authors:  D A Flick; G E Gifford
Journal:  J Immunol Methods       Date:  1984-03-30       Impact factor: 2.303

6.  A macrophage factor inhibits adipocyte gene expression: an in vitro model of cachexia.

Authors:  F M Torti; B Dieckmann; B Beutler; A Cerami; G M Ringold
Journal:  Science       Date:  1985-08-30       Impact factor: 47.728

7.  Passive immunization against cachectin/tumor necrosis factor protects mice from lethal effect of endotoxin.

Authors:  B Beutler; I W Milsark; A C Cerami
Journal:  Science       Date:  1985-08-30       Impact factor: 47.728

8.  Recombinant human tumor necrosis factor-alpha: effects on proliferation of normal and transformed cells in vitro.

Authors:  B J Sugarman; B B Aggarwal; P E Hass; I S Figari; M A Palladino; H M Shepard
Journal:  Science       Date:  1985-11-22       Impact factor: 47.728

Review 9.  Weight loss associated with an endotoxin-induced mediator from peritoneal macrophages: the role of cachectin (tumor necrosis factor).

Authors:  A Cerami; Y Ikeda; N Le Trang; P J Hotez; B Beutler
Journal:  Immunol Lett       Date:  1985       Impact factor: 3.685

10.  Purification of cachectin, a lipoprotein lipase-suppressing hormone secreted by endotoxin-induced RAW 264.7 cells.

Authors:  B Beutler; J Mahoney; N Le Trang; P Pekala; A Cerami
Journal:  J Exp Med       Date:  1985-05-01       Impact factor: 14.307

View more
  107 in total

1.  [Graft-versus-Host Disease (GvHD) - an update : Part 1: Pathophysiology, clinical features and classification of GvHD].

Authors:  R Travnik; M Beckers; D Wolff; E Holler; M Landthaler; S Karrer
Journal:  Hautarzt       Date:  2011-02       Impact factor: 0.751

2.  Graft-versus-host-disease-associated donor cell engraftment in an F1 hybrid model is dependent upon the Fas pathway.

Authors:  T Iwasaki; T Hamano; K Saheki; T Kuroiwa; Y Kataoka; Y Takemoto; A Ogata; J Fujimoto; E Kakishita
Journal:  Immunology       Date:  2000-01       Impact factor: 7.397

3.  [Cutaneous graft-versus-host disease].

Authors:  S Karrer
Journal:  Hautarzt       Date:  2003-05       Impact factor: 0.751

4.  Rapamycin generates anti-apoptotic human Th1/Tc1 cells via autophagy for induction of xenogeneic GVHD.

Authors:  Shoba Amarnath; Francis A Flomerfelt; Carliann M Costanzo; Jason E Foley; Jacopo Mariotti; Daniel M Konecki; Anu Gangopadhyay; Michael Eckhaus; Susan Wong; Bruce L Levine; Carl H June; Daniel H Fowler
Journal:  Autophagy       Date:  2010-05-16       Impact factor: 16.016

5.  Innate immune activation by the viral PAMP poly I:C potentiates pulmonary graft-versus-host disease after allogeneic hematopoietic cell transplant.

Authors:  Christine V Kinnier; Tereza Martinu; Kymberly M Gowdy; Julia L Nugent; Francine L Kelly; Scott M Palmer
Journal:  Transpl Immunol       Date:  2010-11-09       Impact factor: 1.708

6.  Host interleukin 6 production regulates inflammation but not tryptophan metabolism in the brain during murine GVHD.

Authors:  Ludovic Belle; Vivian Zhou; Kara L Stuhr; Margaret Beatka; Emily M Siebers; Jennifer M Knight; Michael W Lawlor; Casey Weaver; Misato Hashizume; Cecilia J Hillard; William R Drobyski
Journal:  JCI Insight       Date:  2017-07-20

7.  Dynamics of M1 macrophages in oral mucosal lesions during the development of acute graft-versus-host disease in rats.

Authors:  K Seno; M Yasunaga; H Kajiya; K Izaki-Hagio; H Morita; M Yoneda; T Hirofuji; J Ohno
Journal:  Clin Exp Immunol       Date:  2017-09-28       Impact factor: 4.330

8.  Pathological and virological features of arenavirus disease in guinea pigs. Comparison of two Pichinde virus strains.

Authors:  J F Aronson; N K Herzog; T R Jerrells
Journal:  Am J Pathol       Date:  1994-07       Impact factor: 4.307

Review 9.  Genetics of allogeneic hematopoietic cell transplantation. Role of HLA matching, functional variation in immune response genes.

Authors:  John A Hansen; Effie W Petersdorf; Ming-Tseh Lin; Steven Wang; Jason W Chien; Barry Storer; Paul J Martin
Journal:  Immunol Res       Date:  2008       Impact factor: 2.829

Review 10.  Antibiotic-mediated modification of the intestinal microbiome in allogeneic hematopoietic stem cell transplantation.

Authors:  J Whangbo; J Ritz; A Bhatt
Journal:  Bone Marrow Transplant       Date:  2016-08-15       Impact factor: 5.483

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.